Subscribe to the Antiviral InteliStrat Database
You need to be a member to get access to the database. Many options are available for subscribing along with subscription rates, as described on the Services page.
Below is a sample of information available upon subscribing to the database. This includes detailed product files that can be visualized by clicking on the products name appearing in the grid.
Log into your account
Database Sample
Sponsor(s)  |
Product | Type of product | Mode of action | Viral family | Virus | Status-1 | Status-2 | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Sanofi Pasteur / Sanofi Aventis (global presence) | Dengvaxia® ChimeriVax-Dengue; ChimeriVax Dengue; CYD Dengue; CYD-TDV; CYD TDV |
Vaccine | Recombinant, viral expr vector | Flaviviridae | Dengue virus | Market | Approved for market in Mexico (Dec. 2015), Philippines (Dec. 2015), Brazil (Dec. 2015), Salvador (Jan. 2016); Filings for marketing authorization completed in several countries endemic for Dengue Fever virus; See Remarks | |||
|
Argos Therapeutics (formerly Merix Bioscience; USA) | AGS-004 AGS004; AGS 004; Arcelis |
Vaccine | Other | Retroviridae | HIV (Human Immunodeficiency virus) | Phase II | 2 Phase II trials completed (2011 and 2015) | |||
|
GlaxoSmithKline (GSK; global presence) | Retrovir® zidovudine; azidothymidine; AZT; BW A509U; Zydowin |
Inhibitor | NRTI | Retroviridae | HIV (Human Immunodeficiency virus) | Market | Approved for market in US (Mar. 19, 1987) and other markets | |||
|
Pharmacor (acquired by Procyon/Ambrilia Biopharma; Canada) (no longer in operation) | P-1946 | Inhibitor | PI | Retroviridae | HIV (Human Immunodeficiency virus) | Preclinical | Lead compound | |||
|
TaiMed Biologics (Taiwan, USA) | Trogarzo™ Ibalizumab; Ibalizumab-uiyk; TNX-355; TNX355; TNX 355; Hu5A8; TMB-355; TMB355; TMB 355 |
Antibodies | EI | Retroviridae | HIV (Human Immunodeficiency virus) | Market | Orphan Drug status; Fast track status; Breakthrough Therapy Designation (Feb. 2015); Priority Review status granted by FDA (Jun. 2017), and FDA approval for US market granted on Mar. 06, 2018; See Remarks | |||
|
Novartis (global presence) | Focetria® Focetria® A(H1N1); Focetria A(H1N1); Focetria A/H1N1; Influenza A (H1N1) 2009 Monovalent Vaccine |
Vaccine | Non-recombinant protein vaccine | Orthomyxoviridae | Swine Influenza virus | Market | Approved by EMEA for distribution in EU (Sept. 29, 2009) under control of health authorities and governments; WHO-Prequalification status; No longer available (2015); See Remarks | |||
|
Abbott / AbbVie (global presence) | A-837093 A-837,093; A837093; A 837093 |
Inhibitor | RNA Pol IN | Flaviviridae | HCV (Hepatitis C virus) | Preclinical | No further development | |||
|
Abbott / AbbVie (global presence) | Paritaprevir Veruprevir; ABT-450; ABT450; ABT 450 |
Inhibitor | PI | Flaviviridae | HCV (Hepatitis C virus) | Market | Approved for market in US (Dec. 2014)and other markets as part of combination therapy called Viekira Pak; See Remarks | |||
|
Novavax (USA) (formerly DynCorp) | RSV-F VLP vaccine RSV vaccine; RSV F-VLP vaccine; RSV F VLP vaccine; RSV F vaccine |
Vaccine | Recombinant protein vaccine | Paramyxoviridae | RSV (Respiratory Syncytial virus) | Phase III | New Phase II initiated after failure of a Phase III trial, Jan. 2017; Fast track designation granted by FDA (2016); See Remarks | |||
|
Janssen Therapeutics (formerly Tibotec) / Janssen Pharmaceuticals / Johnson & Johnson (global presence) | TMC353121 TMC-353121; TMC 353121 |
Inhibitor | EI | Paramyxoviridae | RSV (Respiratory Syncytial virus) | Preclinical | ||||
|
|||||||||||